Tempus AI, Inc. (TEM)

Market Cap	9.24B +2.6%
Revenue (ttm)	1.11B +72.6%
Net Income	-203.88M
EPS	-1.19
Shares Out	177.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,135,368
Open	51.04
Previous Close	50.78
Day's Range	50.43 - 52.65
52-Week Range	36.22 - 104.32
Beta	n/a
Analysts	Buy
Price Target	83.90 (+61.5%)
Earnings Date	Feb 24, 2026

About TEM

Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharma...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Jun 14, 2024
• Employees: 2,400
• Stock Exchange: NASDAQ
• Ticker Symbol: TEM
• Website: https://www.tempus.com

Financial Performance

In 2024, Tempus AI's revenue was $693.40 million, an increase of 30.38% compared to the previous year's $531.82 million. Losses were -$746.33 million, 180.6% more than in 2023.

Analyst Summary

According to 11 analysts, the average rating for TEM stock is "Buy." The 12-month stock price target is $83.9, which is an increase of 61.50% from the latest price.

Price Target

$83.9

(61.50% upside)

Analyst Consensus: Buy